Suso Platero, PhD, to become Division Director of Molecular Genetics and Pathology at the FDA’s Office of Health Technology 7

Life Science Partner has recruited Suso Platero, PhD, to become Division Director of Molecular Genetics and Pathology at the FDA’s Office of Health Technology 7 (OHT7).

In this role, Dr. Platero will oversee the regulatory evaluation of molecular diagnostic products and companion diagnostics, ensuring rigorous scientific and regulatory standards are applied to cutting-edge innovations in oncology, immuno-oncology, and rare diseases. 

Suso Platero, PhD

In this role, Dr. Platero will oversee the regulatory evaluation of molecular diagnostic products and companion diagnostics, ensuring rigorous scientific and regulatory standards are applied to cutting-edge innovations in oncology, immuno-oncology, and rare diseases. 

Platero has over twenty years of experience in drug discovery, diagnostics, and precision medicine. As the former Chief Scientific officer at Discovery Life Sciences and Vice President of Biomarkers and Companion Diagnostics at Vertex Pharmaceuticals, he developed biomarker-driven strategies to support clinical trials and regulatory submissions.   

Career Highlights and Contributions

Platero has over twenty years of experience in drug discovery, diagnostics, and precision medicine.

As the former Chief Scientific officer at Discovery Life Sciences and Vice President of Biomarkers and Companion Diagnostics at Vertex Pharmaceuticals, he developed biomarker-driven strategies to support clinical trials and regulatory submissions.   

Platero has always been on the cutting edge of developing companion diagnostics. At Janssen Pharmaceuticals, he led the team that discovered and developed the companion diagnostic for Balversa©, approved by the FDA. 

At LabCorp and Covance, Dr. Platero created and headed the Biomarker Solutions Center, where he led a team responsible for developing and commercializing companion diagnostics for global regulatory approval. 

“Platero joins a team of leaders that we have recruited for FDA oversight of this rapidly changing field of IVD diagnostics,” notes Tom Callaway, MD, MBA, Founder of Life Science Partner.  “Throughout his career, Dr. Platero has collaborated with key opinion leaders and regulatory agencies to accelerate the development of precision medicine approaches in oncology and immunology.”

Dr. Platero holds a PhD in Cell and Molecular Biology from St. Louis University, where he focused on the functional analysis of chromatin domains in eukaryotic cells. He also earned a Master of Science in Cell Biology and Molecular Biophysics from Columbia University and a Bachelor of Science in Chemistry and Microbiology from the University of Pittsburgh.

Read More About Life Science Partner’s Recruitment for the FDA

Here are some of featured Press Releases that describe our executive placements and involvement with the FDA:

FDA Regulatory Leadership For Medtech/IT Convergence

Life Science Partner has partnered with the FDA to recruit leaders that can create innovative pathways for early-stage companies to be better prepared for the regulatory review and clearance process. In close collaboration with Jeff Shuren, MD, JD, Head of the Center for Devices and Radiological Health (CDRH) for the FDA, Life Science Partner recruited Doug…

Read More

Something went wrong. Please refresh the page and/or try again.

/0 Comments/by

Christine Vietz to become Deputy Office Director, Personalized Medicine | FDA

Life Science Partner has recruited Christine Vietz, PhD, formerly Senior Vice President of Product Development at Foundation Medicine, to become the Deputy Office Director, Personalized Medicine, for the FDA’s CDRH OHT 7 (In Vitro Diagnostics).

Vietz will oversee the 60+ person Division of Molecular Genetics and Pathology, and will continue to build out the emerging organization of regulatory scientists  comprising the Personalized Medicine Team.

As the leader of the Personalized Medicine Team, she will also serve as a liaison to the medical device industry, as well as to the scientific and healthcare communities for personalized medicine related issues.

Christine Vietz, PhD FDA

Under Vietz’s leadership, OHT7 seeks to grow its expertise in genetically based disease diagnosis and identification of targets for therapeutic intervention.

Vietz has over 20 years of leadership experience across diagnostic assay development, regulatory affairs, and clinical laboratory operations. 

Under Vietz’s leadership, OHT7 seeks to grow its expertise in genetically based disease diagnosis and identification of targets for therapeutic intervention. Vietz has over 20 years of leadership experience across diagnostic assay development, regulatory affairs, and clinical laboratory operations. 

Career Highlights and Contributions

Before joining the FDA, Dr. Vietz served as Senior Vice President of Product Development at Foundation Medicine. Her leadership enabled the company to achieve multiple industry firsts, including securing FDA approval for the FoundationOne CDx pan-tumor comprehensive genomic profiling assay under the Breakthrough Devices Program.

During her tenure at Foundation Medicine, she developed the regulatory strategy and built the diagnostic development teams that continued to expand Foundation Medicine’s IVD portfolio with approval of the liquid biopsy assay, FoundationOne Liquid CDx, as well as the many subsequent companion diagnostic claims added to the approved assays over the subsequent years. 

“Christine stands out in her extraordinary ability to bring cutting-edge diagnostics tied to biopharmaceuticals development through the regulatory process,” said Tom Callaway, MD, founder of Life Science Partner. “Patients will have better outcomes thanks to the FDA’s forward-thinking, particularly in this era of AI and personalized therapeutics.“

Vietz earned her PhD in Biomedical and Medical Engineering and her Bachelor of Science in Chemical Engineering from the University of Rochester. Vietz’s commitment to innovation, regulatory excellence, and operational efficiency makes her uniquely suited for her new leadership role at the FDA.

Read More About Life Science Partner’s Recruitment for the FDA

Here are some of featured Press Releases that describe our executive placements and involvement with the FDA:

David McMullen, MD, Recruited as Director, Office of Neurological and Physical Medicine Devices (OHT5), FDA Center for Devices and Radiological Health (CDRH)

Life Science Partner has recruited David McMullen, MD, to serve as Director for The Office of Neurological and Physical Medicine Devices (OHT5), Center for Devices and Radiological Health (CDRH) at the Federal Drug Administration.  The CDRH facilitates medical device innovation by advancing regulatory science, providing industry with predictable, consistent, transparent, and efficient regulatory pathways, and assuring…

Read More
/0 Comments/by

Ross Segan, MD, to Become FDA CDRH’s Office Director, Product Evaluation & Quality

Life Science Partner has recruited Ross (Rusty) Segan, MD, formerly Chief Medical Officer of Olympus and Integrated Leader, Pre-Clinical, Clinical, and Medical Affairs at DuPuy Synthes, to the FDA to become Director of the Office of Product Evaluation and Quality (OPEQ) in the FDA’s Center for Devices and Radiological Health (CDRH).

Segan’s New Role and Responsibilities at the FDA

In this role, Dr. Segan is responsible for setting the strategy and overseeing Device-Specific Offices, the Office of Clinical Evidence and Analysis, and the Office of Regulatory Programs. His leadership ensures quality end-to-end device evaluation and consistent interpretation and application of regulatory policy and guidance.

Ross "Rusty" Segan, MD, FDA CDRH's Office Director, Product Evaluation & Quality

With his extensive background in medical and scientific affairs, Dr. Segan brings a wealth of experience from his global leadership roles at Olympus, Johnson & Johnson, and Covidien, where he led the development and implementation of clinical and regulatory strategies that significantly improved clinical outcomes and upheld patient safety.

Career Highlights and Contributions to the Medical Device Industry

Before joining the FDA, Dr. Segan held several prominent positions in the medical device industry. As Chief Medical Officer of Olympus, he was pivotal in driving the company’s medical safety initiatives and fostering innovation across the global portfolio. At Johnson & Johnson’s DuPuy Synthes, he led Pre-Clinical, Clinical, and Medical Affairs for the $9 billion orthopedic and medical device division.

His career also includes leadership roles at Covidien, overseeing a diverse portfolio of clinical studies, healthcare economics, and reimbursement strategies. Across these roles, Dr. Segan consistently demonstrated his ability to integrate business strategy with scientific excellence, driving transformation in medical technologies that improved patient care worldwide.

“Rusty brings a wealth of experience in science, medicine, and, most importantly, organizational leadership,” said Thomas Callaway, MD, Founder of Life Science Partner.  His former colleagues widely praised his management skills, an asset that will help him succeed in leading the teams and infrastructure within the FDA’s CDRH. 

Dr. Segan’s educational background complements his extensive career in the medical technology industry. He earned his Medical Doctor degree from UMDNJ-Robert Wood Johnson Medical School and holds a Master of Business Administration with specializations in Entrepreneurship, Innovation, and Leadership from New York University’s Stern School of Business.

Before his medical education, Dr. Segan earned a Bachelor of Science from Salisbury State University and a Master of Science in Athletic Training from West Virginia University. 

His clinical training includes general surgery residencies at Thomas Jefferson University Hospital and Cooper Hospital/University Medical Center and a clinical fellowship in minimally invasive surgery at the University of Maryland.

This diverse academic background has equipped Dr. Segan with a unique combination of medical, business, and leadership expertise, enabling him to excel in advancing healthcare technology and regulatory practices globally.

Read More About Life Science Partner’s Recruitment for the FDA

Here are some of featured Press Releases that describe our executive placements and involvement with the FDA:

/0 Comments/by

Scott Hirsch Joins SOLIUS Board of Directors – Life Science Partner

Former CEO of Solta Medical joins SOLIUS Board of Directors.

Life Science Partner is proud to have recruited Scott Hirsch to join the SOLIUS Board of Directors. With extensive experience leading medical device companies and steering business units to success, Hirsch brings a wealth of regulatory expertise and business acumen to SOLIUS.

In collaboration with newly appointed CEO Chris Kiple, JD, Hirsch will assist in fundraising, scaling operations, and launching SOLIUS’ proprietary UVB light therapy technology, designed to treat patients with low Vitamin D levels, including a groundbreaking at-home therapy device.

Hirsch’s Professional Background

Hirsch was drawn to SOLIUS following Valeant’s $250 million acquisition of Solta Medical, a former division of Bausch Health Companies, where Hirsch spearheaded significant achievements. Solta became a recognized leader in the aesthetics industry with a portfolio of products that included the popular Thermage®, Fraxel®, Clear + Brilliant®, and VASERlipo® systems. Hirsch’s expertise in direct-to-consumer business models will drive SOLIUS’ commercialization and regulatory strategies.

“With an impressive background in financing and a proven track record for executing innovative commercialization plans, Hirsch’s strategic vision and dynamic leadership will play a crucial role in SOLIUS’ success,” says Tom Callaway, MD, Founder of Life Science Partner.

Before his tenure as CEO of Solta, Hirsch held leadership roles across several Bausch business units, including President of the Bausch Foundation, President of Ortho Dermatologics, and OraPharma.

Before that, Hirsch was an investor and portfolio manager on Wall Street at Citadel and was Vice President at Plural Investments. He also held the position of Lead Equity Research Analyst for Specialty Pharmaceuticals and Global Generics at Credit Suisse.

Hirsch holds a Bachelor of Fine Arts from the Rhode Island School of Design and an MBA in Finance and Healthcare Management from The Wharton School.

Life Science Partner is also pleased to announce the recruitment of Chris Kiple, JD, former CEO of Ventec Life Systems, as SOLIUS’s Chief Executive Officer.

Learn More About Medical Device Industry Recruitment
/0 Comments/by

Lori Gould Recruited to Lead the Middle Tennessee Research Institute in Nashville, TN

Lori Gould, MTRI Executive Director

Working closely with Life Science Partner, the Middle Tennessee Research Institute has recruited Lori A. Gould as its new Executive Director.

MTRI:  Not for Profit Research Institute for the Veterans Administration, Nashville TN

Middle Tennessee Research Institute (MTRI), based in Nashville, TN, is a non-profit organization dedicated to advancing research and education for the U.S. Department of Veterans Affairs.

MTRI collaborates with the Tennessee Valley Healthcare System to enhance treatment and educational opportunities for veterans, employing a model established by federal legislation in 1988.

This organization is part of a nationwide network of 83 similar non-profit research organizations.

Executive Director Requirements

MTRI partnered with Life Science Partner to recruit its new Executive Director to drive growth and expand its non-VA funding sources. The key characteristics sought included: 

  • Entrepreneurial leadership with proven skills in organizational management.
  • Financial oversight experience with budgets up to $10 million.
  • Strategic marketing with developing successful promotional campaigns.
  • Management of teams, including recruiting staffing, planning, and budgeting capabilities to enhance research and patient care within the organization.

A Personal and Professional Project

This was both a professional and personal project for Life Science Partner’s Founder, Tom Callaway, MD.  He and his team worked closely with his first cousin, Dr. Carol Callaway-Lane, DNP, ACNP-BC. Callaway-Lane was Board President of Middle Tennessee Research Institute (MTRI), and his medical school classmate, Stokes Peebles, Jr, MD. 

Peebles is on the MTRI Board and is a Professor in the Department of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, at Vanderbilt University Medical Center. He is the Principal Investigator of The Peebles Lab, which investigates mechanisms regulating lung inflammation.

Tom Callaway commented, “It was a pleasure working with my alma mater and two very close friends to recruit Lori to lead this innovative partnership between the VA and external research funding sources to improve the healthcare of our nation’s veterans. Nashville-based MTRI is a leading not-for-profit research organization and will accelerate its rising status and funding under Lori Gould’s tested leadership and vision.”

Lori Gould Is Recruited to Lead MTRI

Lori Gould was the perfect fit. She was most recently Executive Director of the Veterans Health Research Institute of CNY Inc. (VHRI) in Syracuse, NY, and has demonstrated outstanding leadership and commitment in her roles spanning over thirty years.  Gould’s career is marked by a continuous progression in roles with increasing responsibility, particularly in managing financial and operational systems.

Her leadership qualities, combined with a strong background in finance and technology, have contributed to the growth of the organizations she has worked with, setting a high standard in nonprofit management and operational excellence. Her career trajectory is a testament to her dedication, strategic vision, and capability to adapt and thrive in dynamic environments.

Lori Gould’s Leadership Spotlight

Since September 2010, Gould has led VHRI, a multi-site non-profit corporation (NPC) serving the Syracuse VA Medical Center and the Finger Lakes Health Care System. As Executive Director, she has effectively managed the overall operations, ensuring compliance with board directives and applicable federal and state requirements.

Her leadership spans various critical functions, including financial management, human resources, and grant administration. Gould’s ability to negotiate Cooperative Research and Development Agreement (CRADA) terms and maintain a robust pool of research coordinators exemplifies her strategic foresight and operational excellence. She has represented VHRI at various significant meetings and has solidified the organization’s position within the community.

Before this role, from September 2006 to September 2010, Gould served as the Chief Financial Officer for the same institute. Her responsibilities included overseeing all accounting functions, ensuring compliance with relevant regulations, and managing VHRI’s fiscal performance. Her strategic development of annual operating budgets and oversight of clinical trial and federal grant budgets highlight her adeptness in financial governance and resource allocation.

Between September 2005 and June 2006, Gould enriched her career portfolio as a Staff Accountant at the Diocese of Syracuse.   From October 2001 to June 2002, Gould was the Manager of Technology & Analysis at Agri-Services Agency LLC, East Syracuse, NY. She designed and implemented a new technology system to meet the company’s present and future needs, showcasing her foresight in technological integration and system management.

Gould’s contributions included revamping the accounting and billing systems and implementing collection procedures that notably reduced the receivable balance, reflecting her impact on streamlining financial operations.

Gould’s Early Career Highlights

Earlier in her career, from June 1996 to November 1997, Gould served as the Purchasing Manager at Applied Theory Communications, where she established a new purchasing department and significantly reduced expenses through strategic vendor agreements.

Her Financial/Budget Analyst role at Chesterton Company from June 1993 to November 1995 further highlights her expertise in financial analysis and budget management.

The early years of her career were spent as a Fiscal Manager at Broome BOCES – RIC in Binghamton, NY, from July 1986 to January 1993

Gould began her professional journey after graduating with a B.S. in Business Administration/Finance from the Rochester Institute of Technology in 1986.

Life Science Partner – Recruiting Transformational Leaders Like Gould

Since 2002, Life Science Partner has combined scientific knowledge with business discipline to identify and recruit the brightest talent, provide strategic advice, and connect companies with the best candidates to make their enterprises more successful.

Our targeted, high-quality executive search services meet the specific needs of medical device, biotechnology, pharmaceutical, and healthcare organizations.

How LSP Recruits Differently – Through Partnership

Life Science Partner has designed a unique and thorough approach to bringing our clients the transformational leaders needed to take their businesses to the next level.

Life Science Partner will work with your organizational needs, including the corporate culture and factors for success in the role, in order to:

  • Create a job description that captures the opportunity to attract the best and most qualified talent.
  • Strategically research, identify, and contact prospective candidates and sources.
  • Assess our best prospective candidates via telephone, Zoom, and face-to-face interviews.
  • Update you with continuous feedback on our progress in weekly meetings, written reports, and telephone calls.
  • Provide you with candidate assessment letters that convey our recommendations and reservations.
  • Conduct in-depth references on the leading candidates with a written report.
  • Assist you in negotiating an acceptable offer, with a fiduciary responsibility to our client.
  • Partner with you to ensure a successful transition into the new role, including a one-year search-again guarantee of success.
Contact Life Science Partner

Happy Client and Its New Leader

With the recruitment of Lori Gould to lead the Nashville-based Middle Tennessee Veterans Research Institute, Life Science Partner again has demonstrated its proven formula can deliver results and provide organizations with transformative leaders. 

Congratulations to our client, Dr. Carol Callaway-Lane, DNP, ACNP-BC, Board President, and her new Executive Director, Lori Gould.

Learn More About Chief Executive Functions
/0 Comments/by

Stewart McNaull, PhD, Joins Wheeler Bio as SVP, Chief Business Officer

Life Science Partner announces the recruitment of Stewart McNaull, PhD, to develop commercialization and expand access of Wheeler Bio’s products and service offerings.

Stewart McNaull

Wheeler Bio, a quickly growing CDMO, retained Life Science Partner to recruit their President and Chief Operating Officer in 2022 to accelerate their advancement as an industry leader in biologics development services. After a thorough search, the company hired a seasoned executive to lead their strategic business opportunities and joint ventures. Early in 2023, Wheeler Bio contacted Life Science Partner to repeat the search to better fulfill the needs of the company.

As a result of reconvening the search and in partnership with the Wheeler Bio Board, Life Science Partner recruited Stewart McNaull, PhD, former Vice President and Business Unit Head, Biologics and Vaccines for Resilience, to serve as Wheeler’s Senior Vice President, Chief Business Officer.

“With his extensive commercial experience in the CDMO industry, McNaull will have a tremendous impact on the establishment of Wheeler’s strategic alliances and sales channel development.”

Tom Callaway, MD, Founder of Life Science Partner.

While at Resilience, McNaull managed the business operations and strategy for the Biologics and Vaccines commercial franchise encompassing seven development and manufacturing sites worldwide. Leading the design and execution of the company’s network development and sales/marketing strategy, McNaull was successful in spear-heading rapid growth and expansion of the company’s Biologics and Vaccines business.

Prior to his role at Resilience, McNaull served as Senior Vice President, Business Development for KBI Biopharma where he had global responsibility for the company’s sales and marketing strategy. Earlier in his career, McNaull served in business development and scientific engineering leadership roles for Diosynth Biotechnologies and Bayer Biologics.

McNaull received his Bachelor of Science degree in Chemical Engineering from North Carolina State University and his PhD in Chemical Engineering from the Georgia Institute of Technology.

Learn More About Chief Executive Functions
/0 Comments/by

Troy Tazbaz joins the FDA to lead the Digital Health Division and Center of Excellence

Former Oracle SVP, Troy Tazbaz will lead the effort to advance AI and ML for healthcare and help orchestrate a new regulatory environment for digital healthcare.

Life Science Partner announces the recruitment of the FDA’s new Division Director for Digital Health and Director for the Digital Health Center of Excellence to prepare the agency to partner with innovators and create regulatory guidance for the application of Artificial Intelligence within the convergence of healthcare IT and medical devices.

Formerly, the Senior Vice President, Industry Business Unit for Oracle, Troy Tazbaz will step into this new critical role created within the Office of Strategic Partnerships and Technology Innovation in the FDA’s Center for Devices and Radiological Health (CDRH).

Troy Tazbaz

“A thought-leader within the integrated world of cloud-based AI technology, Tazbaz is a thoughtful problem solver with a track record of successfully bridging multiple constituencies to accelerate AI adoption to improve efficiencies including patient care outcomes”

Tom Callaway, MD, Founder of Life Science Partner

Tazbaz will partner with a broad range of national and global government agencies, institutions, academia, and various organizations representing patients, consumers, and healthcare professionals. Tazbaz will be responsible for building the FDA’s key resources for establishing digital health guidelines and efficient regulatory pathways for the integration of digital and cloud-based technologies.

Tazbaz joins the FDA after recently serving as Senior Vice President of Strategy and Operations for Industry Business Unit responsible for developing Oracle’s industry-specific operating technologies. Earlier in his tenure at Oracle, he led various strategic initiatives such as global cloud data center expansion planning, developing Oracle’s industry strategy, and the launching of Healthcare Business Unit.  

Life Science Partner is pleased to continue their partnership with the Center for Devices and Radiological Health at the FDA on leadership projects underway for the Office of Product Evaluation and Quality.

About Life Science Partner

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare information technology fields.

Learn More About Chief Medical or Regulatory Leaders

Read More About Life Science Partner’s Recruitment for the FDA

Here are some of featured Press Releases that describe our executive placements and involvement with the FDA:

/0 Comments/by

Brian Berquist, PhD, Joins Wheeler Bio as Chief Development Officer

Life Science Partner announces the newest recruit for emerging CDMO:

Wheeler Bio, a CDMO, retained Life Science Partner to recruit their Chief Development Officer to lead their process development team and accelerate their platform as a technological leader within the CDMO space. Beginning in January 2023, Brian Berquist, PhD, will lead the team in Wheeler Bio’s newstate-of-the-art Oklahoma City facility, where they have revolutionized the speed of drug discovery and democratized the innovation-to-impact process.

Brian Berquist

Berquist’s solid scientific background and ability to problem-solve in an entrepreneurial environment makes him well-suited for the R&D and innovation advancements he will undertake at Wheeler Bio.

Tom Callaway, MD, Founder of Life Science Partner

In his new role as Chief Development Officer, Berquist will oversee operations including cell line development, cell culture process development, purification development, analytical development, and formulation development. He will serve as Wheeler Bio’s scientific subject-matter expert and will lead his team in the continuous improvement of advancing the company’s R&D and technology platforms.

Prior to joining Wheeler Bio, Berquist served as the Vice President of Process Development and Analytical Sciences for iBio CDMO where he directed the process development and analytical sciences divisions for both development and characterization of proprietary products and services. Earlier in his career, Berquist served in key scientific and research roles for Caliber Biotherapeutics and Texas A&M Health Science Center.

Berquist holds a Bachelor of Science degree in Biochemistry and Molecular Biology from the University of Massachusetts, and he earned his PhD in Molecular Medicine and Molecular and Cellular Biology from the University of Maryland.

About Life Science Partner

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Learn More About Chief Scientific and Technology Leader Recruitment
/0 Comments/by

Detra Glinatsis Joins Alloy Therapeutics as Vice President, Business Development and Sales

Life Science Partner announces the recruitment of Detra Glinatsis to lead Alloy Therapeutics’ enterprise sales growth within the CDMO industry.

Alloy Therapeutics retained Life Science Partner to recruit their Vice President, Business Development and Sales to manage and accelerate their growth in biologics development services. Through a community of over 100 partners and developers, Alloy seeks to democratize access to pre- competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics.

Detra Glinatsis

Life Science Partner is pleased to announce that Detra Glinatsis, former Senior Director, Business Development from AGC Biologics with experience building and leading a sales organization, will lead Alloy Therapeutics sales team.

“As a resourceful self-starter with a talent for streamlining sales processes, Glinatsis will be an instrumental addition for supporting Alloy Therapeutics’ rapid growth within the CDMO space.”

Tom Callaway, MD, Founder of Life Science Partner

In her new role at Alloy, Glinatsis will lead a team to build out the company’s customer base and sales infrastructure. She will identify and manage strategic partnerships, alliances, and joint ventures to contribute to Alloy’s expansion within the market. Additionally, Glinatsis will have the responsibility to facilitate Alloy’s participation in industry events, creation of collateral materials, and marketing of Alloy’s position within the CDMO space.

Prior to joining Alloy, Glinatsis served in various global business development roles for CDMOs and pharmaceutical companies including AGC Biologics, Sartorius, Rentschler Biopharma, Inventiv Health and Patheon Biologics. She holds a Bachelor of Science Degree in Biology from the University of Akron.

About Life Science Partner

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Learn More About Chief Executive Functions
/0 Comments/by

Roger Lias, PhD, Joins Wheeler Bio as President and Chief Operating Officer

Life Science Partner announces the recruitment of Roger Lias, PhD, to Wheeler Bio to advance their expansion as cutting-edge biologics CDMO.

Roger Lias Wheeler Bio

Wheeler Bio, a CDMO, retained Life Science Partner to recruit their President and Chief Operating Officer to accelerate their growth as an industry leader in biologics development services. With a new state-of-the-art Oklahoma City facility, Wheeler Bio has revolutionized the speed of drug discovery with their novel hub-and-spoke concept and Portable CMC® platform that fast-tracks the pathway to IND.

After a nationwide search campaign, Roger Lias, PhD, former Chief Commercial Officer of Vibalogics, was recruited by Life Science Partner to serve as Wheeler Bio’s President and Chief Operating Officer beginning in September 2022.

“Lias’ well-established credibility in the biopharma CDMO industry combined with his entrepreneurial leadership experience made him an absolute fit for growing Wheeler Bio into the global partner of choice for biological companies.”

Tom Callaway, MD, Founder of Life Science Partner

Lias will hit the ground running joining the Wheeler Bio team at the BioProcess International Conference in Boston this month, September 2022. In his new role Lias will be responsible for spearheading strategic business opportunities, alliances and joint ventures and will lead a scalable business operations team keeping Wheeler’s technology development and functions aligned with the corporate strategy as industry demand increases.

Prior to joining Wheeler Bio, Lias served as the Chief Commercial Officer for Vibalogics, a Private Equity-backed CDMO that was acquired by Recipharm AB in February, 2022.  He has an extensive track record of entrepreneurial successes including Stelis Biopharma, Avid Biosciences, Allergan, Eden Pharma, Cytovance and KBI Biopharma.

Lias holds a Bachelor of Science degree in Physiology and Biochemistry from the University of Southampton in the United Kingdom. He earned his PhD from Clare College, University Cambridge.

About Life Science Partner

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Learn More About Chief Executive Functions
/0 Comments/by